Swiss National Bank decreased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,410,346 shares of the company's stock after selling 273,000 shares during the quarter. Swiss National Bank owned about 0.28% of Kenvue worth $115,511,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the company. Assetmark Inc. grew its holdings in Kenvue by 29.9% in the 3rd quarter. Assetmark Inc. now owns 67,796 shares of the company's stock worth $1,568,000 after buying an additional 15,593 shares in the last quarter. Atria Investments Inc boosted its position in Kenvue by 13.8% during the 3rd quarter. Atria Investments Inc now owns 111,326 shares of the company's stock worth $2,575,000 after acquiring an additional 13,500 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of Kenvue in the third quarter worth $213,000. Victory Capital Management Inc. grew its stake in shares of Kenvue by 66.2% in the third quarter. Victory Capital Management Inc. now owns 1,328,074 shares of the company's stock worth $30,718,000 after purchasing an additional 528,849 shares in the last quarter. Finally, KBC Group NV increased its holdings in shares of Kenvue by 114.0% during the third quarter. KBC Group NV now owns 966,160 shares of the company's stock valued at $22,348,000 after purchasing an additional 514,580 shares during the period. Institutional investors own 97.64% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently issued reports on KVUE shares. Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Piper Sandler increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Canaccord Genuity Group boosted their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $23.75.
View Our Latest Stock Analysis on KVUE
Kenvue Trading Up 0.6 %
Shares of NYSE KVUE traded up $0.15 during mid-day trading on Wednesday, hitting $23.49. 9,646,888 shares of the company traded hands, compared to its average volume of 16,084,529. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $44.89 billion, a price-to-earnings ratio of 44.31, a PEG ratio of 2.62 and a beta of 1.25. The business has a 50 day moving average of $21.94 and a two-hundred day moving average of $22.41.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
